Profile data is unavailable for this security.
About the company
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
- Revenue in USD (TTM)16.94m
- Net income in USD-122.54m
- Incorporated2004
- Employees55.00
- LocationCara Therapeutics Inc400 Atlantic Street, Suite 500STAMFORD 06901United StatesUSA
- Phone+1 (203) 406-3700
- Fax+1 (203) 567-1510
- Websitehttps://www.caratherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OncoCyte Corp | 1.38m | -40.66m | 37.88m | 43.00 | -- | 2.02 | -- | 27.41 | -4.94 | -4.94 | 0.1682 | 2.05 | 0.018 | -- | 1.34 | 32,139.54 | -51.95 | -35.11 | -58.73 | -39.71 | 22.07 | -- | -2,890.23 | -2,373.36 | -- | -157.69 | 0.00 | -- | 56.89 | -- | -34.84 | -- | 55.41 | -- |
Vyne Therapeutics Inc | 423.00k | -28.50m | 38.21m | 10.00 | -- | 0.4512 | -- | 90.33 | -5.26 | -5.42 | 0.021 | 5.83 | 0.0067 | -- | -- | 42,300.00 | -44.91 | -108.41 | -50.67 | -138.57 | -- | -- | -6,738.06 | -1,907.10 | -- | -- | 0.00 | -- | -11.11 | -47.51 | 17.89 | -- | -- | -- |
NRX Pharmaceuticals Inc | 0.00 | -25.65m | 38.74m | 2.00 | -- | -- | -- | -- | -2.06 | -2.06 | 0.00 | -1.54 | 0.00 | -- | -- | -- | -200.56 | -120.57 | -- | -168.40 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 24.14 | -- | -- | -- |
Mink Therapeutics Inc | 0.00 | -20.59m | 38.78m | 31.00 | -- | -- | -- | -- | -0.5964 | -0.5964 | 0.00 | -0.585 | 0.00 | -- | -- | 0.00 | -175.32 | -- | -3,661.37 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 19.77 | -- | -- | -- |
DURECT Corp | 8.32m | -23.28m | 39.11m | 48.00 | -- | 4.71 | -- | 4.70 | -0.8653 | -0.8653 | 0.2976 | 0.2674 | 0.176 | 0.7021 | 6.87 | 143,465.50 | -49.23 | -37.34 | -167.81 | -53.44 | 80.56 | 91.83 | -279.77 | -139.11 | 0.9575 | -47.70 | 0.6377 | -- | -55.67 | -10.96 | 21.82 | -- | -10.98 | -- |
Xilio Therapeutics Inc | 0.00 | -70.96m | 39.50m | 73.00 | -- | 1.43 | -- | -- | -2.57 | -2.57 | 0.00 | 0.7474 | 0.00 | -- | -- | 0.00 | -73.11 | -- | -96.98 | -- | -- | -- | -- | -- | -- | -144.29 | 0.00 | -- | -- | -- | 13.40 | -- | -- | -- |
Bright Green Corp | 0.00 | -13.13m | 39.92m | 5.00 | -- | 3.54 | -- | -- | -0.0732 | -0.0732 | 0.00 | 0.0594 | 0.00 | -- | -- | 0.00 | -64.24 | -- | -97.68 | -- | -- | -- | -- | -- | -- | -5,488.51 | 0.0181 | -- | -- | -- | 52.54 | -- | -- | -- |
Cara Therapeutics Inc | 16.94m | -122.54m | 40.12m | 55.00 | -- | 1.35 | -- | 2.37 | -2.26 | -2.26 | 0.3118 | 0.5452 | 0.1392 | 1.34 | 4.35 | 307,963.60 | -100.70 | -35.76 | -115.83 | -40.82 | 75.18 | -- | -723.49 | -162.10 | 5.20 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
Natural Alternatives International, Inc. | 120.20m | -3.31m | 40.31m | 317.00 | -- | 0.4793 | 30.03 | 0.3353 | -0.5646 | -0.5646 | 20.53 | 13.56 | 0.8091 | 3.63 | 12.77 | 379,183.00 | -2.23 | 4.90 | -2.56 | 5.93 | 8.85 | 15.98 | -2.75 | 3.80 | 2.44 | -2.71 | 0.0996 | 0.00 | -9.91 | 3.06 | -76.46 | -20.74 | 27.08 | -- |
Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -40.09m | 40.48m | 15.00 | -- | -- | -- | -- | -1.60 | -1.60 | 0.00 | -0.0482 | 0.00 | -- | -- | 0.00 | -303.75 | -- | -1,499.90 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.92 | -- | -- | -- |
Brainstorm Cell Therapeutics Inc | 0.00 | -15.53m | 40.51m | 29.00 | -- | -- | -- | -- | -0.3227 | -0.3227 | 0.00 | -0.0811 | 0.00 | -- | -- | 0.00 | -276.90 | -117.19 | -- | -231.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.18 | -- | -45.34 | -- |
Movano Inc | 852.00k | -27.91m | 40.58m | 30.00 | -- | -- | -- | 47.63 | -0.5593 | -0.5593 | 0.0168 | -0.0263 | 0.0779 | -- | 2.12 | 28,400.00 | -254.99 | -151.50 | -559.26 | -188.58 | -42.61 | -- | -3,275.47 | -- | 0.5147 | -- | -- | -- | -- | -- | 3.45 | -- | 4.24 | -- |
Acurx Pharmaceuticals Inc | 0.00 | -16.05m | 41.35m | 4.00 | -- | 6.86 | -- | -- | -1.17 | -1.17 | 0.00 | 0.3807 | 0.00 | -- | -- | 0.00 | -194.65 | -- | -283.87 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.55 | -- | -- | -- |
Matinas BioPharma Holdings Inc | 0.00 | -23.25m | 41.38m | 32.00 | -- | 2.46 | -- | -- | -0.107 | -0.107 | 0.00 | 0.0669 | 0.00 | -- | -- | 0.00 | -80.36 | -44.62 | -86.16 | -48.25 | -- | -- | -- | -2,344.60 | -- | -- | 0.0014 | -- | -65.62 | 55.71 | -9.26 | -- | -16.46 | -- |
Hcw Biologics Inc | 3.93m | -27.39m | 41.61m | 45.00 | -- | 4.76 | -- | 10.60 | -0.7547 | -0.7547 | 0.1083 | 0.2311 | 0.1062 | -- | 6.79 | 87,258.22 | -74.07 | -- | -97.78 | -- | 29.61 | -- | -697.59 | -- | -- | -146.89 | 0.4863 | -- | -57.72 | -- | -67.74 | -- | -- | -- |
Immuneering Corp | 0.00 | -54.18m | 42.11m | 65.00 | -- | 0.5349 | -- | -- | -1.86 | -1.86 | 0.00 | 2.65 | 0.00 | -- | -- | 0.00 | -55.37 | -- | -58.58 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -5.86 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 31 Mar 2024 | 3.06m | 5.60% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 2.44m | 4.47% |
Disciplined Growth Investors, Inc.as of 31 Mar 2024 | 1.82m | 3.32% |
Chescapmanager LLCas of 31 Mar 2024 | 1.70m | 3.11% |
Farallon Capital Management LLCas of 31 Mar 2024 | 1.56m | 2.85% |
Rosalind Advisors, Inc.as of 31 Mar 2024 | 1.55m | 2.83% |
Renaissance Technologies LLCas of 31 Mar 2024 | 1.33m | 2.44% |
Geode Capital Management LLCas of 31 Mar 2024 | 1.02m | 1.87% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.00m | 1.84% |
Stifel Nicolaus & Co., Inc. (Investment Management)as of 31 Mar 2024 | 741.37k | 1.36% |